---
title: "PTH(1-34) Analog (Generic Teriparatide)"
canonical_url: https://peptidelibrary.app/library/pth-1-34-analog
description: "PTH(1–34) analog class. The FDA-approved drug is teriparatide (Forteo/Bonsity). Research or compounded vials are not those products."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# PTH(1-34) Analog (Generic Teriparatide)

PTH(1-34) Analog (Generic Teriparatide), also called Teriparatide analog or PTH (1-34), is a PTH fragment in the PTH1 receptor agonist class. This entry covers generic and compounded preparations of the parathyroid hormone(1-34) fragment, the same active sequence as teriparatide.

PTH(1–34) analog class. The FDA-approved drug is teriparatide (Forteo/Bonsity). Research or compounded vials are not those products.

Also known as: Teriparatide analog, PTH (1-34).

Categories: Muscle/Recovery, Experimental.

## Classification

- Type: PTH fragment / research or compounded
- Mechanism class: PTH1 receptor agonist
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

This entry covers generic and compounded preparations of the parathyroid hormone(1-34) fragment, the same active sequence as teriparatide. The pharmacology is the receptor biology of PTH1: intermittent daily exposure increases osteoblast number and survival and produces net bone formation, whereas continuous elevation shifts the balance toward RANKL-mediated osteoclastic resorption and bone loss. The distinction between the approved product and compounded material is not pharmacological but one of manufacturing, characterisation and regulatory oversight, and identity and purity of non-approved preparations are not assured.

Targets: PTH1 receptor.

Origin: Synthetic PTH(1–34).

## Properties

- Molecular formula: C181H291N55O51S2
- Molecular weight: ≈4118 g/mol
- CAS number: 52232-67-4
- Half-life: About 1 hour after subcutaneous injection (Forteo label)
- Studied routes: Subcutaneous

## Evidence

- Evidence level: FDA Approved
- Highest documented: Regulatory review (FDA label)
- Human trials: 1
- Controlled human trials: 1
- Preclinical sources: 0
- Latest source: 2010

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Teriparatide Injection (Teva) — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: Postmenopausal women with osteoporosis at high risk for fracture; men with primary or hypogonadal osteoporosis at high risk; men and women with glucocorticoid-induced osteoporosis at high risk. Treatment of osteoporosis [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d371f0f7-d492-4481-b360-051456d56d65)
2. Teriparatide Injection (Alvogen) — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: The same three osteoporosis populations. Treatment of osteoporosis [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b007339-dd0d-f019-5e0a-9b1b0f75011c)
3. FORTEO (teriparatide injection) — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: Postmenopausal women with osteoporosis at high risk for fracture; men with primary or hypogonadal osteoporosis at high risk; men and women with glucocorticoid-induced osteoporosis at high risk [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aae667c5-381f-4f92-93df-2ed6158d07b0)
4. Aspenberg P et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010. 2010. Controlled human trial. Population: Postmenopausal women aged 45 to 85 with a distal radial fracture treated by closed reduction without surgery (n=102) [Source](https://pubmed.ncbi.nlm.nih.gov/19594305/)

## Safety

Side effects: Hypercalcemia; Orthostasis; Leg cramps.

Risks: Osteosarcoma warning on labeled PTH analogs; Unapproved vials are not Forteo.

Human safety basis: FDA prescribing information

Key limitations: Not approved by the FDA for any use..

## Regulatory status

PTH(1-34) Analog (Generic Teriparatide) is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- Availability: Research-Only

## Frequently asked questions

### What is PTH(1-34) Analog (Generic Teriparatide)?

PTH(1–34) analog class. The FDA-approved drug is teriparatide (Forteo/Bonsity). Research or compounded vials are not those products.

### How does PTH(1-34) Analog (Generic Teriparatide) work?

This entry covers generic and compounded preparations of the parathyroid hormone(1-34) fragment, the same active sequence as teriparatide. The pharmacology is the receptor biology of PTH1: intermittent daily exposure increases osteoblast number and survival and produces net bone formation, whereas continuous elevation shifts the balance toward RANKL-mediated osteoclastic resorption and bone loss.

### Is PTH(1-34) Analog (Generic Teriparatide) FDA approved?

No. PTH(1-34) Analog (Generic Teriparatide) is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of PTH(1-34) Analog (Generic Teriparatide)?

Reported half-life for PTH(1-34) Analog (Generic Teriparatide) is ~1 h (sc); same as Forteo reference. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What peptides are similar to PTH(1-34) Analog (Generic Teriparatide)?

Compounds most often compared with PTH(1-34) Analog (Generic Teriparatide) include Teriparatide, Abaloparatide, BPC-157 and Cardiogen. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [Class-level evidence — PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis. Osteoporos Int, 2025](https://pubmed.ncbi.nlm.nih.gov/40047881/)
- [Class-level evidence — Clinical effects of teriparatide, abaloparatide, and romosozumab. J Bone Miner Metab, 2025](https://pubmed.ncbi.nlm.nih.gov/39009890/)
- [Class-level evidence — Effectiveness and Safety of Treatments to Prevent Fractures. Ann Intern Med, 2023](https://pubmed.ncbi.nlm.nih.gov/36592455/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
